Pharma AI budgets outpace network optimisation investment

LogiPharma Digital Supply Chain Connect research suggests pharmaceutical supply chain professionals are putting artificial intelligence and machine learning ahead of most other technology investments, with 96% of respondents ranking the technologies among their leading priorities. Advanced data analytics followed at 73%, while network optimisation was selected by 53%, leaving a sizeable gap between investment in AI and the infrastructure needed to convert its outputs into operational action.

The survey was conducted among pharmaceutical supply chain professionals ahead of the LogiPharma Digital Supply Chain Connect event later in 2026. The material released with the findings does not disclose the number of respondents, so the percentages describe the priorities of that survey group rather than establishing a representative measure for the pharmaceutical sector as a whole.

Demand planning and forecasting, inventory optimisation, and logistics orchestration were among the leading areas identified for AI deployment. Those applications sit close to some of the most expensive problems in pharmaceutical supply chains, where inaccurate forecasts can produce stock shortages at one end of the network and costly excess inventory at the other, while transport decisions can be constrained by product value, temperature requirements, regulatory controls, and limited replacement capacity.

AI is increasingly being considered as more than an analytical layer. A forecasting model can highlight a likely shortage, while an agentic system may be designed to recommend or initiate actions across inventory, planning, procurement, and logistics workflows. That progression increases the potential operational value of the technology, but it also raises the consequences of weak data, inappropriate permissions, or a poorly governed decision.

Regulatory uncertainty and compliance concerns were identified as the largest barrier to broader adoption in the LogiPharma research. Pharmaceutical operations depend on validated processes, controlled records, traceability, product-quality status, market authorisations, and clearly assigned responsibility, meaning automated decisions have to operate inside a much tighter governance environment than a general business productivity tool.

An AI system that proposes reallocating inventory, changing a route, or selecting an alternative logistics option also needs to understand whether the stock is actually usable in the destination market. Temperature history, batch status, serialisation, quality release, packaging qualification, and customer-specific requirements can all determine whether an apparently efficient recommendation is operationally possible.

More than half of respondents also remained uncertain about whether AI can meaningfully improve disruption prediction and mitigation. That hesitation exposes the difference between detecting a problem and having the network flexibility to respond to it. A system may recognise supplier failure, transport delay, or emerging demand volatility earlier, but advance warning creates limited value if there is no qualified secondary supplier, alternative route, available stock, approved carrier, or spare production capacity.

The 53% ranking for network optimisation is therefore particularly relevant when set beside the 96% figure for AI and machine learning. Visibility and prediction can improve faster than the physical network behind them, creating an operational maturity gap in which organisations can see a disruption developing without having enough approved options to change the outcome.

That issue is already visible in adjacent pharmaceutical technology development. TraceLink’s agentic control tower for life sciences combines analytics, transaction monitoring, reasoning, and governed software agents across a connected healthcare network. The architecture is intended to progress from displaying exceptions towards interpreting them and coordinating controlled action, but its usefulness still depends on reliable data, defined permissions, and the ability of companies and trading partners to execute the recommended response.

Ben Sharples, Event Director at LogiPharma Digital Supply Chain Connect, said: “What’s particularly interesting is that the industry conversation has evolved beyond whether AI has a role to play in pharmaceutical supply chains.” He said current attention is instead turning towards where the technology can create value, how it can be deployed responsibly, and which foundations have to be in place before implementation can succeed.

Those foundations reach beyond the AI model itself. Master data has to be sufficiently consistent for systems to identify the same product, order, site, and shipment across different applications, while planning and execution systems must exchange information quickly enough for a recommendation to remain useful. Organisations also need clear escalation routes, human approval points, and audit records where an automated recommendation touches regulated or safety-critical decisions.

Automation, upskilling, and general digital transformation did not appear as separate headline budget priorities in the survey, despite being common themes in pharmaceutical supply chain programmes. The findings do not establish why respondents ranked them that way, although they may increasingly sit inside larger AI and data programmes rather than being treated as standalone investment categories.

That creates a practical budgeting problem if spending on models and platforms grows faster than spending on integration and operating change. Better forecasting does not automatically rebalance stock, an earlier disruption alert does not create an alternative supplier, and an automated recommendation cannot remove a compliance requirement that still needs human or validated-system approval.

The LogiPharma figures consequently show strong investment intent alongside more cautious expectations about execution. AI and machine learning dominate the reported priorities, but network optimisation sits much lower and more than half of respondents remain unconvinced about disruption mitigation. The next measure of progress will be whether that spending closes the gap between identifying supply chain problems earlier and giving pharmaceutical operations enough controlled flexibility to do something useful about them.